SAN DIEGO–(BUSINESS WIRE)–Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, today announced another record setting month, quarter, and first half performance. The results reflect accelerating adoption across healthcare systems as organizations increasingly prioritize solutions that improve diagnostic accuracy, reduce avoidable costs, and support standardized blood culture collection in response to evolving national regulatory expectations and quality initiatives.
“Our record performance reflects more than a successful quarter, it shows a broader shift in how health systems are approaching blood culture collection,” said Bob Rogers, CEO of Kurin, Inc. “Hospitals are increasingly prioritizing solutions that improve diagnostic accuracy, standardize best practices, and deliver measurable clinical and financial value. We are proud to help lead that transformation.”
During the first half of 2026, Kurin expanded its growing body of clinical evidence through peer-reviewed publications and customer implementations, further strengthening its position as the most clinically studied, commercially available and evidence based automatic blood culture diversion technology.
“Healthcare organizations are looking beyond individual products, they’re seeking trusted partners that can help drive lasting quality improvement,” said Abby Norfleet, EVP of Sales. “Customers are looking for trusted partners who can help them implement technology and help standardize best practices while delivering sustained and measurable performance in patient care, operational efficiency, and financial outcomes. That continued focus is driving strong adoption of Kurin across health systems. “
With consecutive record quarters, accelerating clinical adoption, and an expanding portfolio of peer-reviewed evidence, Kurin remains focused on advancing innovation in blood culture collection, while partnering with healthcare systems to improve diagnostic accuracy, reduce blood culture contamination, and deliver measurable clinical and financial value.
“We’re still in the early stages of what’s coming,” said Tom Thompson, President of Kurin Inc. “Our focus remains simple. We continue building the strongest clinical evidence, developing innovative solutions that fit naturally into clinical workflow, and helping health systems achieve sustainable value from improvements in blood culture quality. We’re excited about the opportunities ahead and continue to invest in our customers and team.”
About Kurin®, Inc.
Kurin is a privately held, certified minority-owned business dedicated to engineering better healthcare through innovative, cost-effective, clinician-approved technologies. Building on the successful invention, clinical adoption, and corporate acquisition of CUROS™ disinfecting port protectors, Kurin is focusing its depth of experience in medical device engineering, marketing, sales, and service to tackle the persistent and costly fallout of false-positive blood cultures. With agile development capabilities and intense customer focus, the Kurin Blood Collection Systems have quickly gained caregiver acceptance, have been proven to sideline skin contaminants during blood culture collection, and are the market-leading solution for blood culture collection best practice.
CUROS™ is a registered trademark of Solventum and Kurin has no connection to Solventum.
Contacts
Media contact:
Jenna Lindgren
646.675.4996
[email protected]
